(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.53%) $79.68
(0.43%) $2.31
(0.56%) $2 353.30
(0.76%) $28.58
(0.21%) $992.90
(-0.01%) $0.927
(-0.17%) $10.85
(-0.04%) $0.798
(0.00%) $92.54
5 days till quarter result
(bmo 2024-05-14)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform...
Stats | |
---|---|
Dagens volum | 226 369 |
Gjennomsnittsvolum | 803 516 |
Markedsverdi | 251.33M |
EPS | $0 ( 2024-03-26 ) |
Neste inntjeningsdato | ( $-0.890 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.97 |
ATR14 | $0.0540 (0.66%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Miller Mary | Sell | 558 | Common Stock |
2024-04-11 | Ra Capital Management, L.p. | Buy | 3 530 000 | Common Stock |
2024-04-11 | Perceptive Advisors Llc | Buy | 2 353 000 | Common Stock |
2024-03-04 | Palani Santhosh | Buy | 32 500 | Stock Option (Right to Buy) |
2024-03-04 | Palani Santhosh | Buy | 0 |
INSIDER POWER |
---|
24.75 |
Last 56 transactions |
Buy: 13 025 326 | Sell: 16 556 327 |
Volum Korrelasjon
Acrivon Therapeutics, Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Acrivon Therapeutics, Korrelasjon - Valuta/Råvare
Acrivon Therapeutics, Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-536 000 (0.00 %) |
EPS: | $-2.74 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $-536 000 (0.00 %) |
EPS: | $-2.74 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-1.10M (0.00 %) |
EPS: | $-1.350 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.260 |
Financial Reports:
No articles found.
Acrivon Therapeutics,
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.